OR WAIT null SECS
July 04, 2024
The companies have restructured their existing collaboration into a licensing agreement that invests in mRNA development.
June 19, 2024
The companies have completed the expansion and qualification phase and now enter a stand-by phase for five years.
May 24, 2024
An ASGCT Panel titled Novel Nucleic Acid and Cell-based Vaccines for Cancer highlights promising mRNA personalized cancer vaccine work.
May 07, 2024
This research focuses on refining the clarification step by assessing the performance of various depth filters. The study explores both conventional cellulose-based and innovative synthetic depth filters, utilizing pneumococcal fermentation harvests from two challenging serotypes.
April 22, 2024
The outcomes of a workshop organized by WHO and ICMRA regarding COVID-19 vaccine strain updates are presented in a report published by regulators.
April 16, 2024
The collaboration will focus on differentiated cancer vaccine candidates in hematological and solid tumor indications to treat unmet medical needs.
March 02, 2024
A tidal wave of questions floats the need for more upstream automation.
February 21, 2024
AstraZeneca has completed its acquisition of Icosavax, gaining the IVX-A12 vaccine candidate that targets RSV and hMPV.
January 11, 2024
Regulators from around the world will gather to help shape the mRNA and RNA therapeutics landscape at an exceptional April 2024 Washington, D.C. convocation.
November 24, 2023
Looking at the role that RSV and pediatric medical practices play in drug shortages.